| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 78.49B | — |
| Operating expense | — | — |
| Net income | 20.99B | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, NVO returned -13.9% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | -3.6% |
| 1 year | -13.9% |
| 5 years | +4.9% |
| 10 years | +152.7% |
| All-time high | $142.74 (Jun 2024) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in NVO would be worth today ›Yes. Novo Nordisk A/S paid 2 dividends over the past 12 months. The most recent was $0.58 per share on Aug 17, 2026. The dividend yield is 3.84%.
Novo Nordisk A/S stock trades on NYSE under the ticker symbol NVO.
Novo Nordisk A/S is part of the Healthcare sector.
Novo Nordisk A/S has a market cap of 206.69B USD, based on the latest quote.
Novo Nordisk A/S is expected to report earnings around Nov 4, 2026. That date is an estimate and has not been confirmed by the company.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
